Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals

AIDS

Volumn 21, Issue 13, 2007, Pages 1701-1710

  Revill, Peter A ^a   Littlejohn, Margaret ^a   Ayres, Anna ^a   Yuen, Lilly ^a   Colledge, Danni ^a   Bartholomeusz, Angeline ^a   Sasaduesz, Joe ^b   Lewin, Sharon R ^c,f   Dore, Gregory J ^d   Matthews, Gail V ^d   Thio, Chloe L ^e   Locarnini, Stephen A ^g  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MONASH UNIVERSITY   (Australia)

^g VIDRL ^*

Author keywords

Core mutant; Hepatitis B virus; HIV hepatitis B virus co infection; Immune escape; Precore mutant

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS GENOME; VIRUS IDENTIFICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DNA, VIRAL; GENE DELETION; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; VIRAL CORE PROTEINS;

EID: 34547739182     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32826fb305     Document Type: Article

References (42)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-S9.
2. Cooley L, Sasadeusz J. Clinical and virological aspects of hepatitis B co-infection in individuals infected with human immunodeficiency virus type-1. J Clin Virol 2003; 26:185-193.
3. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-249.
4. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
5. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
6. Hung YB, Liang JT, Chu JS, Chen KM, Lee CS. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. Hepatogastroenterology 1995; 42:913-918.
7. Mason AL, Wick M, White HM, Benner KG, Lee RG, Regenstein F, et al. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology 1993; 105:237-244.
8. Gunther S, Baginski S, Kissel H, Reinke P, Kruger DH, Will H, Meisel H. Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology 1996; 24:751-758.
9. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174:1565-1570.
10. Preikschat P, Gunther S, Reinhold S, Will H, Budde K, Neumayer HH, et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002; 35:466-477.
11. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
12. Tai PC, Banik D, Lin GI, Pai S, Pai K, Lin MH, et al. Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol 1997; 71:4852-4856.
13. Marschenz S, Endres AS, Brinckmann A, Heise T, Kristiansen G, Nurnberg P, et al. Functional analysis of complex hepatitis B virus variants associated with development of liver cirrhosis. Gastroenterology 2006; 131:765-780.
14. Gunther S, Piwon N, Jung A, Iwanska A, Schmitz H, Will H. Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene. Virology 2000; 273:286-299.
15. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
16. Mai AL, Yim C, O'Rourke K, Heathcote EJ. The interaction of human immunodeficiency virus infection and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol 1996; 22:299-304.
17. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. Aids 1997; 11:597-606.
18. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. Aids 2006; 20:863-870.
19. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. Aids 2003; 17:1649-1657.
20. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45:2495-2501.
21. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
22. Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004; 95:125-149.
23. Yuen KWL, Ayres A, Littlejohn M, Colledge D, Edgley A, Maskill WJ, et al. SEQHEPB: A sequence and analysis program and relational database system for chronic hepatitis B antiviral research. Antiviral Research in press.
24. Bartholomeusz A, Locarnini SA, Ayres A, Thompson G, Sozzi V. Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology 2004; 40 (Suppl 1A):A185.
25. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25:4876-4882.
26. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp 1999; 41:95-98.
27. Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996; 12:357-358.
28. Carlier D, Jean-Jean O, Fouillot N, Will H, Rossignol JM. Importance of the C terminus of the hepatitis B virus precore protein in secretion of HBe antigen. J Gen Virol 1995; 76 (Pt 4):1041-1045.
29. Bowyer SM, van Staden L, Kew MC, Sim JG. A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. J Gen Virol 1997; 78 (Pt 7):1719-1729.
30. Hannoun C, Soderstrom A, Norkrans G, Lindh M. Phylogeny of African complete genomes reveals a West African genotype A subtype of hepatitis B virus and relatedness between Somali and Asian A1 sequences. J Gen Virol 2005; 86:2163-2167.
31. Sugauchi F, Kumada H, Sakugawa H, Komatsu M, Niitsuma H, Watanabe H, et al. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin Infect Dis 2004; 38:1222-1228.
32. Bell SJ, Lau A, Thompson A, Watson KJ, Demediuk B, Shaw G, et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. J Clin Virol 2005; 32:122-127.
33. Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 1991; 88:214-222.
34. Andrei G, Balzarini J, Fiten P, De Clercq E, Opdenakker G, Snoeck R. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J Virol 2005; 79:5863-5869.
35. Okada Y, Streisinger G, Owen JE, Newton J, Tsugita A, Inouye M. Molecular basis of a mutational hot spot in the lysozyme gene of bacteriophage T4. Nature 1972; 236:338-341.
36. Sasadeusz JJ, Tufaro F, Safrin S, Schubert K, Hubinette MM, Cheung PK, Sacks SL. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J Virol 1997; 71:3872-3878.
37. Wilson JB, Hayday A, Courtneidge S, Fried M. A frameshift at a mutational hotspot in the polyoma virus early region generates two new proteins that define T-antigen functional domains. Cell 1986; 44:477-487.
38. Locarnini S, Shaw T, Dean J, Colledge D, Thompson A, Li K, et al. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. J Clin Virol 2005; 32:113-121.
39. Messageot F, Salhi S, Eon P, Rossignol JM. Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences. J Biol Chem 2003; 278:891-895.
40. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31:1037-1044.
41. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78:12725-12734.
42. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997; 71:345-353.